Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock Has Consensus Target Price of $36.25

Nuvectis Pharma logo with Healthcare background
Image from MarketBeat Media, LLC.

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) has received an average rating of "Moderate Buy" from the six brokerages that are covering the company, MarketBeat reports. Two analysts have rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $36.25.

A number of equities research analysts have commented on NVCT shares. Cantor Fitzgerald started coverage on shares of Nuvectis Pharma in a report on Monday, August 24th. They issued an "overweight" rating for the company. Wall Street Zen lowered shares of Nuvectis Pharma from a "hold" rating to a "sell" rating in a report on Saturday, November 7th. Lucid Cap Mkts raised shares of Nuvectis Pharma to a "strong-buy" rating in a research report on Tuesday, September 1st. HC Wainwright restated a "buy" rating and issued a $39.00 target price on shares of Nuvectis Pharma in a research note on Thursday, September 24th. Finally, Zacks Research lowered Nuvectis Pharma from a "hold" rating to a "strong sell" rating in a research report on Thursday, November 5th.

Check Out Our Latest Stock Report on NVCT

Nuvectis Pharma Price Performance

NVCT opened at $19.20 on Wednesday. Nuvectis Pharma has a fifty-two week low of $5.77 and a fifty-two week high of $29.27. The company's 50 day moving average price is $20.41 and its two-hundred day moving average price is $15.29. The firm has a market capitalization of $660.29 million, a price-to-earnings ratio of -10.16 and a beta of -0.21.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.78). As a group, equities research analysts predict that Nuvectis Pharma will post -1.89 EPS for the current year.

Institutional Trading of Nuvectis Pharma

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE boosted its position in Nuvectis Pharma by 10.2% in the first quarter. Bank of America Corp DE now owns 14,847 shares of the company's stock worth $115,000 after purchasing an additional 1,377 shares during the last quarter. Legal & General Group Plc bought a new position in Nuvectis Pharma in the 2nd quarter valued at $31,000. Oppenheimer & Co. Inc. increased its position in shares of Nuvectis Pharma by 17.3% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 86,291 shares of the company's stock valued at $1,822,000 after purchasing an additional 12,725 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Nuvectis Pharma by 67.8% during the 3rd quarter. Goldman Sachs Group Inc. now owns 34,372 shares of the company's stock valued at $726,000 after purchasing an additional 13,892 shares during the last quarter. Finally, Avalon Trust Co purchased a new stake in shares of Nuvectis Pharma during the 2nd quarter valued at $257,000. Institutional investors own 96.77% of the company's stock.

About Nuvectis Pharma

(Get Free Report)

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with serious diseases, particularly cancer. Its research and development programs target molecular pathways that may be relevant to specific tumor types. The company's pipeline includes NXP800, an investigational small-molecule drug designed to inhibit the heat shock factor 1 pathway, and NXP900, an investigational inhibitor of the SRC and YES1 kinases. Nuvectis has studied NXP800 in ovarian cancer and is developing NXP900 for solid tumors; both remain investigational and are not approved medicines.

See Also

Analyst Recommendations for Nuvectis Pharma (NASDAQ:NVCT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Nuvectis Pharma Right Now?

Before you consider Nuvectis Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvectis Pharma wasn't on the list.

While Nuvectis Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines